相关实验视频

Updated: Sep 11, 2025

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

在新辅助免疫疗法后对非小细胞肺癌的免疫微环境的评估:一个病例报告

Martina Leopizzi¹, Angelina Pernazza¹, Emma Rullo²

¹Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University Latina 04100, Italy.

International journal of clinical and experimental pathology

|August 15, 2025

概括

在非小细胞肺癌 (NSCLC) 中的新辅助免疫疗法表明,高的CD137表达和CD137/FOXP3比率与更好的治疗反应相关. 这些标志物可以预测NSCLC患者免疫治疗的有效性.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

免疫检查点抑制剂 (ICI) 在治疗非小细胞肺癌 (NSCLC) 的新辅助疗法中至关重要.
在NSCLC中接受新辅助免疫治疗后,关于瘤微环境 (TME) 的组织学数据很少.
这项研究调查了TME组织学特征和免疫细胞透在NSCLC的后新辅助免疫疗法.

研究的目的:

在新辅助化疗免疫治疗后分析NSCLC瘤微环境中的组织学特征和免疫细胞透.
为了将这些特征与瘤回归度 (TRG) 和治疗反应相关联.

主要方法:

评估了四名NSCLC患者的手术样本,这些患者对新辅助治疗的反应各不相同.
免疫组织化学 (IHC) 用于分析包括T细胞 (CD3,CD4,CD8),B细胞 (CD20,CD138),NK细胞 (CD56),巨细胞 (CD68) 和激活标记物 (CD137,FOXP3) 在内的标记物.
免疫细胞计数和标志物表达与TRG和临床反应相关.

主要成果:

高TRG和治疗响应与三级淋巴体结构,低细胞毒性CD8+T细胞计数,高CD137表达,高CD137/FOXP3比率和低PD-L1表达有关.
CD137表达和CD137/FOXP3比率成为重要的激活标志物.
在高TRG病例中,低细胞毒性细胞计数可能与免疫治疗后评估时间有关.

结论:

CD137和CD137/FOXP3比率是用新辅助免疫疗法治疗NSCLC的重要免疫细胞激活标志物.
这些标记物可以作为治疗反应的预测指标.
需要进一步的研究来验证它们在更大的队列中的预测价值.

关键词:

在NSCLCLC中,我们可以看到.免疫微观环境免疫微环境免疫疗法免疫疗法淋巴细胞淋巴细胞

更多相关视频

Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample

Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample

Published on: November 21, 2023

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...